Novo Nordisk Balance Sheet Health
Financial Health criteria checks 4/6
Novo Nordisk has a total shareholder equity of DKK120.5B and total debt of DKK57.0B, which brings its debt-to-equity ratio to 47.3%. Its total assets and total liabilities are DKK397.4B and DKK276.9B respectively. Novo Nordisk's EBIT is DKK125.5B making its interest coverage ratio -275.2. It has cash and short-term investments of DKK74.9B.
Key information
47.3%
Debt to equity ratio
DKK 56.97b
Debt
| Interest coverage ratio | -275.2x |
| Cash | DKK 74.88b |
| Equity | DKK 120.52b |
| Total liabilities | DKK 276.92b |
| Total assets | DKK 397.44b |
Recent financial health updates
No updates
Recent updates
Novo Nordisk: Just The Right Price (Rating Upgrade)
Dec 11Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Nov 25Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
Nov 06Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Oct 21Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Sep 18Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now
Sep 10Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Financial Position Analysis
Short Term Liabilities: NVO's short term assets (DKK195.2B) do not cover its short term liabilities (DKK208.4B).
Long Term Liabilities: NVO's short term assets (DKK195.2B) exceed its long term liabilities (DKK68.6B).
Debt to Equity History and Analysis
Debt Level: NVO has more cash than its total debt.
Reducing Debt: NVO's debt to equity ratio has increased from 8.2% to 47.3% over the past 5 years.
Debt Coverage: NVO's debt is well covered by operating cash flow (207.5%).
Interest Coverage: NVO earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 04:53 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novo Nordisk A/S is covered by 71 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |